Women’s Health Video Recap—November 12, 2025

This biweekly women’s health video brings you the latest breakthroughs in menopause care, ovarian cancer treatments, and exciting innovations in the space.

Watch Our Video Summary Capturing Top Women’s Health News from the Last Two Weeks

Dive deeper

📚 View the full Women’s health archive on our research hub page.

Transcript

Welcome to the latest edition of Women’s Health Updates, covering breakthroughs in the past two weeks. Brought to you by LucidQuest.

The U.S. Food and Drug Administration has removed the black box warning on hormone therapy for menopause. Previously, these treatments had been under scrutiny due to concerns about cardiovascular risks, stroke, breast cancer, and dementia. This significant change is expected to increase prescriptions, particularly among women under 60, allowing for safer and longer use of hormone replacement therapy. As a result, women now have more treatment options, improving management of their health during menopause.

In Canada, the country’s drug agency has recommended that public drug plans cover Elahere, a treatment for platinum-resistant ovarian cancer. Developed by AbbVie, Elahere has shown to significantly reduce disease progression and improve survival rates. This endorsement is a major step forward, offering women with ovarian cancer a much-needed treatment after more than a decade without new options in this critical area.

In the United States, Gilead’s Trodelvy has failed in a Phase 3 trial for first-line treatment of HR+/HER2-negative metastatic breast cancer. The drug did not meet the primary endpoint of progression-free survival. However, secondary endpoint results suggest potential benefits in overall survival. Despite this, the failure is a setback for Gilead’s efforts to position Trodelvy as a key treatment in breast cancer care, continuing its mixed clinical track record.

The World Health Organization has launched an online course aimed at improving early breast cancer detection. Developed in collaboration with the European Society for Medical Oncology, the course helps healthcare professionals utilize the IARC Atlas for early detection. This initiative is part of global efforts to enhance breast cancer diagnosis and outcomes through interactive and flexible learning for those in the field.

Together Women’s Health has expanded its reach in Tennessee through a partnership with WOMEN Obstetrics & Gynecology. This collaboration brings more than 15 healthcare professionals into TWH’s growing network across multiple states. The expansion strengthens access to vital women’s health services, particularly in underserved regions, ensuring that more women can access comprehensive healthcare.

In a push for innovation, Nestlé Health Science has partnered with Australian Catholic University to accelerate advancements in women’s health, longevity, and weight management. The collaboration will support research and start-ups focused on turning nutrition into scalable solutions for women’s health, potentially leading to transformative products that could improve the quality of life and health outcomes for women worldwide.

Koning Health has made significant strides in breast imaging with the installation of its Vera Breast CT system in leading medical centers globally. This system provides non-compression, true 3D imaging, which is essential for more accurate breast cancer detection. With its growing presence, Vera Breast CT promises to revolutionize breast cancer screening and improve outcomes for women everywhere.

Allegheny Health Network’s West Penn Hospital has become the first in the U.S. to perform a hysterectomy using a new robotic-assisted surgery system in a clinical trial. This cutting-edge procedure aims to evaluate the safety and effectiveness of robotic-assisted hysterectomy for gynecological surgeries. If successful, this advancement could significantly improve the surgical experience for women, offering minimally invasive options with faster recovery times.

Stay ahead in Women’s Health research! Like, share, and subscribe for our updates. Visit www.lqventures.com
or email us at info@lqventures.com for expert healthcare consulting. See you next time!

Why It Matters

Hormone therapy label changes: The FDA’s move to lift the black box warning on menopause hormone therapies could significantly change the landscape of treatment for women, providing safer long-term options [1].
Elahere for ovarian cancer: Canada’s decision to back Elahere for ovarian cancer sets the stage for broader access to a promising new treatment option [2].
Trodelvy setbacks: Gilead’s ongoing challenges with Trodelvy in metastatic breast cancer highlight the complexities of oncology drug development and competition in the space [3].
Breast cancer early detection course: The WHO’s new course will equip healthcare professionals with the skills needed to detect breast cancer earlier, improving survival rates globally [4].
TWH’s expansion in Tennessee: Together Women’s Health’s growth into Tennessee ensures more women have access to high-quality healthcare services [5].
Nestlé’s research partnerships: Nestlé’s investment in women’s health innovation could lead to breakthroughs in nutrition and weight management that directly impact women’s health [6].
Koning’s breast imaging innovation: The continued rollout of Koning’s Vera Breast CT could transform breast cancer detection by offering a more accurate and less invasive method of imaging [7].
Robotic-assisted surgery for hysterectomy: AHN West Penn’s participation in the Medtronic clinical trial represents a key step in improving minimally invasive options for women undergoing gynecological surgery [8].

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Women’s health archive on our research hub page.

FAQ

Why is the FDA removing the black box warning on hormone therapy for menopause?

The FDA is removing the warning after new evidence showed that hormone therapy, especially when started early in menopause, can provide significant benefits with manageable risks [1].

What’s the significance of Elahere’s approval in Canada?

Elahere’s potential to improve survival rates in ovarian cancer patients, especially those with platinum-resistant cancers, marks a major advancement in treatment after a decade of limited options [2].

What happened with Gilead’s Trodelvy in the latest breast cancer trial?

Trodelvy failed to meet the primary endpoint of progression-free survival in a first-line metastatic breast cancer trial, adding to its mixed track record in clinical trials [3].

What is Koning’s contribution to women’s health?

Koning’s Vera Breast CT system is advancing breast cancer screening by providing accurate, non-compression 3D imaging, significantly improving early detection and patient care [7].

Entities / Keywords

FDA; hormone therapy; menopause
Canada; Elahere; ovarian cancer
Gilead; Trodelvy; metastatic breast cancer
WHO; IARC; breast cancer detection
Together Women’s Health; WOMEN Obstetrics & Gynecology
Nestlé; women’s health; longevity
Koning; Vera Breast CT; breast imaging
AHN West Penn; robotic surgery; hysterectomy